P01.052 Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux -M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomus...

od van den Bent, M, French, P, Eoli, M, Sepulvado, J, Walenkamp, A, Weller, M, Looman, J, Ansell, P, Gorlia, T, Golfinopoulos, V
izdano v Neuro Oncol (2018)

P14.41 Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC-26101 trial

od Furtner, J, Genbrugge, E, Gorlia, T, Bendszus, M, Nowosielski, M, Golfinopoulos, V, Weller, M, van den Bent, M J, Wick, W, Preusser, M
izdano v Neuro Oncol (2019)

P01.066 Patients with EGFR amplification but without EGFRvIII expression have improved benefit compared to those with EGFRvIII expression in samples of the INTELLANCE 2/EORTC 1410...

od French, P J, Kros, J, de Heer, I, Ansell, P, Looman, J, Bain, E, Morfouace, M, Gorlia, T, Golfinopoulos, V, van den Bent, M
izdano v Neuro Oncol (2018)

EH1.1 Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion, an int...

od van den Bent, M. J., Erridge, S., Vogelbaum, M., Nowak, A., Sanson, M., Brandes, A. A., Golfinopoulos, V., Gorlia, T., Kros, J. M., Baumert, B. G.
izdano v Neuro Oncol (2016)

P01.12 Stability of actionable mutations in primary and recurrent glioblastomas

od French, P. J., Taphoorn, M., Weyerbrock, A., Sanson, M., Hoeben, A., Lukavoca, S., Lombardi, G., Hanse, M., Watts, C., Golfinopoulos, V., McDermott, U., Robe, P.
izdano v Neuro Oncol (2017)

OS5.1 Sequence of bevacizumab and lomustine in patients with first progression of a glioblastoma: phase II EORTC study 26101

od Wick, W., Stupp, R., Gorlia, T., Bendszus, M., Brandes, A. A., Voss, M. J., Le Rhun, E., Clement, P. M., Golfinopoulos, V., van den Bent, M.
izdano v Neuro Oncol (2016)

P14.54 Association of EGFR Expression and Copy Number with Outcome in Depatux-m (ABT-414) Randomized Phase II Study of the EORTC Brain Tumor Group

od van den Bent, M J, Gorlia, T, Sun, Y, Kular, R, Looman, J, Bain, E E, Robberts-Rapp, L, Ansell, P J, Golfinopoulos, V, French, P
izdano v Neuro Oncol (2019)

OS5.3 Stability of actionable mutations in primary and recurrent glioblastomas

od Draaisma, K., Taphoorn, M., Weyerbrock, A., Sanson, M., Gorlia, T., Golfinopoulos, V., Kros, J. M., Robe, P. A., van den Bent, M. M. J., French, P. J.
izdano v Neuro Oncol (2016)

OS5.7 First results of the randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact 1st recurrence grade II and III glioma

od Idbaih, A., Clement, P. M., Vos, F. Y. F., Platten, M., Mulholland, P., Taphoorn, M. J. B., Lewis, L., Golfinopoulos, V., Gorlia, T., van den Bent, M. J.
izdano v Neuro Oncol (2016)

PL3.2 Trabectedin for recurrent WHO grade II or III meningioma: a randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)

od Preusser, M, Silvani, A, Le Rhun, E, Soffietti, R, Lombardi, G, Sepulveda, J, Brandal, P, Beaney, R, Bonneville-Levard, A, Lorgis, V, Bromberg, J, Erridge, S, Cameron, A, Marosi, C, Golfinopoulos, V, Gorlia, T, Weller, M, Wick, W
izdano v Neuro Oncol (2019)

PL3.3 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/...

od van den Bent, M J, Erridge, S, Vogelbaum, M A, Nowak, A K, Sanson, M, Brandes, A A, Wick, W, Clement, P M, Baurain, J F, Mason, W, Wheeler, H, Weller, M, Aldape, K, Wesseling, P, Kros, J M, Tesileanu, C M S, Golfinopoulos, V, Gorlia, T, Baumert, B G, French, P J
izdano v Neuro Oncol (2019)